Read More

Vigil Neuroscience, Inc. Has Received A Response Letter From The FDA Regarding The Partial Clinical Hold On Its Drug VG-3927, Stating That Additional Non-Clinical Data Is Needed To Exceed The Maximum Exposure Limit In The Phase 1 Trial

- SEC FilingOn Thursday, October 12, 2023, Vigil Neuroscience, Inc. (the "Company") provided an update on the Company's small molecule TREM2 agonist, VG-3927. The Company announced that it received the 30-day

VIGL

Read More

Vigil Neuroscience Announces Update On Its Small Molecule TREM2 Agonist Program; Company Expects To Receive Additional Details From FDA Within Next 30 Days; Will Work Closely With FDA To Address Partial Clinical Hold

- Announced VG-3927 as lead candidate to enter clinical development for potential treatment of Alzheimer's Disease -- IND for VG-3927 now open; Phase 1 clinical trial in healthy volunteers allowed to proceed with partial

VIGL